Aptamer Group PLC Notice of Results and Investor Presentation
October 17 2024 - 1:00AM
RNS Regulatory News
RNS Number : 5031I
Aptamer Group PLC
17 October 2024
17 October
2024
Aptamer Group
plc
("Aptamer", the "Company" or the "Group")
Notice of Results and
Investor Presentation
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable innovation in
the life sciences industry, will announce its full year results for
the year ended 30 June 2024 on Tuesday, 22 October 2024.
The Company is pleased to announce
that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson,
Chief Financial Officer will provide a live presentation relating
to the full year results via Investor Meet Company on Tuesday, 22
October 2024 at 2:00 pm GMT.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard or at any time
during the live presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Aptamer Group plc
via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
Investors who already follow Aptamer
Group plc on the Investor Meet Company platform will automatically
be invited.
- Ends -
For
further information, please contact:
|
Aptamer Group plc
Arron Tolley
|
+44 (0) 1904 217
404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368
3550
|
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
|
Northstar Communications Limited - Investor
Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary
Optimer® platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers. Optimer binders
are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is
currently worth over $170 billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORMFBRTMTJBBJI
Aptamer (LSE:APTA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From Nov 2023 to Nov 2024
